Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather than permanently altering the genome.

$70M funding will catalyze a bold new initiative led by Jennifer Doudna and Jill Banfield to apply precision genome editing to microbial communities. BERKELEY, Calif.--(BUSINESS WIRE)--The Audacious ...

With such striking effects, many scientists see modulating the microbiomes as a promising avenue for improving human health and wellbeing. In recent years, researchers have shown that tweaking the ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...